IL21 and neoplasm: In contrast, using a CT26 colon carcinoma model to evaluate the combinatorial therapy, only IL-21 and mAb CTLA-4 combination showed efficient results, five of eight mice presented complete regression of tumor with the IL-21 and mAb PD-1 combination having no antitumor effects in this model.